Ruben Malmberg

Statistics

Publications

Citations

H-Index

Active since

2015

Affiliations

Erasmus MC Cancer Institute(Current)

Erasmus MC

University Medical Center Groningen

Ruben Malmberg is an author at Erasmus MC Cancer Institute specializing in clinical pharmacology, pharmacology, and pharmacokinetic-pharmacodynamic modeling.

ORCID

Publications per year

2015–2024

Publications

The added value of H2 antagonists in premedication regimens during paclitaxel treatment

Juul M. Cox, Leni van Doorn, Ruben Malmberg et al. · British Journal of Cancer · 2021 · 26 citations · Full text

Medicine, Oncology, Pharmacology +11

Effect of alternative dosing strategies of pembrolizumab and nivolumab on health-care emissions in the Netherlands: a carbon footprint analysis

Ruben Malmberg, Jurrien H Loosveld, Hans-Peter Schilte et al. · The Lancet Planetary Health · 2024 · 20 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model

Sherwin K. B. Sy, Ruben Malmberg, Aoi Matsushima et al. · International Journal of Antimicrobial Agents · 2015 · 15 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +11

Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective

Geeske F. Grit, Esmée van Geffen, Ruben Malmberg et al. · Lung Cancer · 2024 · 13 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

1–4 of 4